“It's time to go beyond the condom.”

Table of Contents
Letter from the Executive Director.................................................................1
Organizational Growth................................................................................2
Thank You For Your Generous Giving!........................................................3
Projects & Activities..................................................................................4
MCI In the Media.........................................................................................6
Articles........................................................................................................8
2014/2015 Staff, Directors, & Advisers.......................................................10
MCI 2014/2015 Financial Report.................................................................16
Letter from the Executive Director

Dear Friends,

Having incorporated in June of 2014, this past year was our first full year. The Parsemus Foundation provided our seed money while DKT International provided ongoing support. In our short time, we've already made strides with public outreach and advancing research.

We've become the go-to experts for the media, having been published in dozens of international media: The Nation, Vice, Mother Jones, The Telegraph, The Huffington Post, Men’s Fitness, NPR, and more. Our website has become one of the main sites people seek out to learn about new male contraceptives. We're starting a conversation.

Our board and advisers extend to the foremost experts in the field on male contraception. We leverage this expertise to help others, such as Spacefill Discovery, the research team behind a novel kinase inhibitor, and Airlangga University with Gendarussa. Additionally, we want to make sure men have access to existing contraceptives, so we've collaborated with World Vasectomy Day and started a petition to get vasectomies covered under the Affordable Care Act. Plus we're already excited about projects for 2016.

Thank you. Your support helps bring us closer to a day where effective reversible options exist for men and their partners. We hope you enjoy our 2015 annual report!

With Great Devotion,

Male Contraception Initiative

Aaron Hamlin, MPH, Esq
Executive Director

Board of Directors
Dr. David Sokal, Chair
Carol Sloan, Vice-Chair
Dr. Mitch Eddy, Treasurer
Beverly Tucker, Secretary
Emily Dorman, Director
Deb Levine, Director
Robert Miller, Director
Gail King, Director
Organizational Growth

Unique Website Visitors

Year

Unique Visitors

2014

2015

Application of Google Grants Adwords for Traffic Generation

Social Media Growth

Year

Followers/Likes

Facebook

Twitter

YouTube

337% Growth in Social Media
Thank You For Your Generous Giving!
Aggregate Giving through 2015

Donations < $1,000

230+ Donors

$1,000 - $4,999

Emily Dorman, Mitch Eddy, Pam Frye, Charles Monteith, David Sokal,
John Stanbeck, Beverly Tucker

$5,000 - $9,999

Benito and Frances C Gaguine Foundation

$50,000 - $99,999

The Parsemhus Foundation

$100,000+

DKT International
Projects & Activities

Media Development

Infographic - A Sparse History of Contraception

Artist Bianna Cruz helped us with one of our favorite media pieces, an infographic timeline detailing the history of contraception—including the lack thereof for male contraception. (Infographic with blog entry)

Organizational Video – It's Time to Go Beyond the Condom

Collaborating with Board Studios, we created a video to introduce our organization and lay out the challenge we face with the absence of an effective, reversible male contraceptive. (Organizational Video)
Male Contraceptive Research Advancement & Support

Spacefill Discovery – Testes-Specific Kinase Inhibitor

We crowdfunded to provide a small grant for Spacefill Discovery, led by Dr. Gary Flynn. The grant helped Spacefill with lab costs to move closer to finding a lead contraceptive compound.

Afterwards, we connected Spacefill with an investor, though that connection ultimately didn’t work out (working with venture capitalists can be challenging). We also put Spacefill in touch with Richard Trilling. Richard specializes in grants within this area and offered initial services to Spacefill pro bono. With this help, Spacefill recently submitted a proposal to the Gates Foundation. Finally, we introduced Dr. Flynn to another experienced contraceptive researcher, Dr. John Herr, whose experience he’s been able to utilize.

Additional Male Contraceptive Advocacy

WorldVasectomy Day

Word Vasectomy Day is an international event organized annually by Jonathan Stack and Dr. Doug Stein. We were able to participate in 2014 and 2015 providing interviews and supporting the event. World Vasectomy day collaborates with dozens of countries and works with urologists to provide thousands of free vasectomies. (World Vasectomy Day)
Petition to Include Vasectomies Under the Affordable Care Act

When we heard that the Affordable Care Act didn't cover male contraceptives, we were shocked. We reached out to our friends at World Vasectomy Day and collaborated on a petition that currently has over 12,000 signatures. We've continued to put pressure on the Department of Health and Human Services, Institute of Medicine, and American Congress of Obstetricians and Gynecologists. Placing vasectomies within the Affordable Care Act not only provides affordable options to men and their partners, but it also sets the stage to provide coverage for future male contraceptives.

(Affordable Care Act Petition)

MCI In the Media

Radio & Podcast Interviews

- Hal Ginsburg Morning Show
- AirTalk (NPR)
- Power FM
- Princeton Radio
- Maggie Linton Show
Online & Print

- **Mouse Study Hints at New 'Male Contraceptive'** – Philly.com
- **Meet The Man Who's Asking The Internet To Help Him Develop Male Contraception** – Think Progress
- **Male contraceptive Pill: More than half of men 'can't wait' to take it** – The Telegraph (UK)
- **Birth Control for Men? Research is Promising but Frustrated by Lack of Funding** – Institute for Ethics and Emerging Technologies
- **Another Step Closer to Male Birth Control Pills** - Smithsonian
- **Will male contraceptive injections transform birth control?** - The Week (UK)
- 'It is a basic right': More men calling for better male birth control options – Raw Story
- **How close are we to male birth control?** - Metro.US
- **Is Male Birth Control Around the Corner?** - Mother Jones
- **What Is the Future of Birth Control for Men?** - The Clean Sheet
- **Male Contraceptive Pill Could Soon Be A Reality Thanks To Crowdfunding Campaign** – Huffington Post (UK)
- **Male Birth Control, Brought to You By Indiegogo** – Men's Fitness
- **This Is What It Takes To Create Contraceptives For Men** – Aplus
- **Birth Control: The New Options Men May Have in the Future** – Cheatsheet
- **Contraception masculine : la pilule passe mal** – Femme Actuelle (France)
- **O anticoncepcional masculino ideal está próximo. E tem até crowdfunding** – Huffington Post (Brazil)
- **Die perfekte Verhütung für den Mann ist da—aber warum nutzen wir sie nicht?** - Vice Motherboard (Germany)
- **Contraception: chérie, je prends la pilule** – Femina (France)
- **La contraception masculine, une méthode bientôt disponible ?** - Madame Figaro (France)
- **Soon, men will be able to take pills for contraception, as well as women** – Metro News (Russia)
- **Det manliga p-pillret är snart här – ”kommer revolutionera våra sexliv”** – Metro News (Sweden)
- **The Male Contraceptive Pill Is Close And Over 50% Of Men 'Can't Wait' To Take It** – Marie Claire
- **Frontiers in Male Contraception** – IEEE Pulse Medicine and Biology
- **Finally, Male Birth Control Pills** – GOOD Magazine
- **The Perfect Birth Control for Men Is Here. Why Can’t We Use It?** - Vice Motherboard (US)
- **Developing Contraceptives for Men Is Really Hard** – Vice Motherboard (UK)
- **Male contraceptive pills to reach US market by 2018** – The Nation
Articles

MCI Website

- Opening Our Doors
- Countdown to World Vasectomy Day
- You Probably Don’t Understand Contraceptive Pregnancy Rates
- The Next Condom Is Ogling Your Bedroom Drawer
- Why Male Contraception: Dr. John Amory
- Why Male Contraception: Aaron Hamlin
- A Sparse History of Male Contraception
- Vasectomy and Prostate Cancer Deja Vu
- Male Contraception Initiative Begins RFPs
- Vasalgel Will Be the First LARC for Men
- Free Birth Control for Women! What About for Men?
- 10 Myths On Male Contraception Debunked
- Male Contraception Perspectives: Rossen
- Live: First Annual MCI Crowdfunding Campaign for Male Contraception
- Male Contraception Perspectives: Marc, North Carolina
- Condoms Are Here To Stay Even With a Male Pill
- First Annual Crowdfunding Recap
- How Does the History of Contraceptive Responsibility Shape Coverage Conversation?
- Birth Control for Men: Promising Research Frustrated by Lack of Funding
- The Affordable Care Act Needs To Cover Vasectomies: Help Make It Happen
- Will Men Take The Pill? Research and Game Theory Say Yes
Third-Party Publications

- **Vasectomy and Prostate Cancer Deja Vu**, 
  Journal of Clinical Oncology

- **Choosing Contraception Based on Effectiveness**, 
  Our Bodies Ourselves Blog

- **The Male Pill Is Coming—and It's Going To Change Everything**, 
  The Telegraph

Authors:

Aaron Hamlin, MPH, Esq
David Sokal, MD
Valerie Tarico, PhD
Lisa Campo-Engelstein, Phd
John Amory, MD
Jonathan Stack
Rossen (Anonymous)
Marc (Anonymous)
2014/2015 Staff, Directors, & Advisers

Below are the staff, directors, and advisers who joined us in 2015 or earlier and have continued with the organization. It is only with our team that we are able to do what we do. We are also thankful for those who assisted with building the organization who are no longer with our team. These people include Clay Lynch, Joe Williams, Nancy Wallace, and Dr. Dominick Shattuck. Thank you!

Staff

Aaron Hamlin, M.Ed., M.P.H., Esq.
Executive Director
Cincinnati, OH

Aaron is a licensed attorney. He has an executive background in the nonprofit sector and has worked as senior in-house counsel within the private sector. At Miami University, his master’s in education coursework focused mainly on statistical analysis. At Indiana University, his research in public health focused on modeling and presenting contraceptive pregnancy rates over longer time scales. Aaron has been interviewed by AirTalk on NPR, Vice.com, IEEE Pulse and others. He’s written for The Telegraph, Bust, and the blog Our Bodies Ourselves.

Board of Directors

David Sokal, M.D.
Chair, Director
Durham, NC

David is an adjunct associate professor of epidemiology at the School of Public Health, UNC-Chapel Hill. He retired from Family Health International (FHI) 360 in 2012 after 25 years working on HIV prevention and contraceptive technology. David led FHI 360’s clinical research on vasectomy techniques. While at FHI 360, David also worked on research studies related to female sterilization. He prepared clinical data for two pre-IND meetings with the FDA, and helped prepare clinical presentations for review panels for two devices for permanent female contraception. The FDA approved both devices. David has also appeared in Mother Jones, Vice, A-Plus, and Good Magazine.
Carol Sloan, M.S.
Vice-Chair, Director
Chapel Hill, NC

Carol Sloan has worked, taught, and published in the areas of endocrinology and reproductive biology for more than 40 years and has extensive experience with hormone assays andrology evaluations. Carol also worked for more than 15 years in reproductive toxicology. She was the Director of the Transgenic Facilities at the University of North Carolina at Chapel Hill (UNC) for more than four years. For 16 years, Carol was the Director of Andrology and Human In Vitro Fertilization Laboratories in obstetrics/gynecology departments at UNC.

Beverley Tucker, M.P.H., M.P.I.A.
Secretary, Director
Durham, NC

Beverly has extensive health- and development-sector experience in program management and evaluation, project design and implementation, as well as management of processes and resources. She has worked with public, private, and academic organizations in Africa, Asia, Europe, and the Americas to improve reproductive health care and services; mitigate impact of HIV/AIDS; enhance emergency relief and services; and strengthen community resources, including the management of local NGOs.

Emily Dorman, M.P.H., M.B.A.
Director
Baltimore, MD

Emily has a professional and academic background in reproductive health and experience in health technology development from both non-profit and private sector perspectives. At Evidera, Emily acts as a scientific consultant to the pharmaceutical industry. In her previous position with the Population Council, Emily supported efforts to license and bring to market Council-developed contraceptive technologies to reduce the unmet need for contraception in developing countries. Emily focused her master’s thesis on the apparent market failure of and potential demand for novel male contraceptive options.
Mitch Eddy, Ph.D.
Treasurer, Director
Durham, NC

Mitch has worked in the field of male reproductive biology throughout his career at academic and government institutions. He is Emeritus Scientist in the Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences (NIEHS), and the National Institutes of Health. His research using knockout mice has provided proof of concept that proteins encoded by the targeted genes are prospective targets for the development of male contraceptives. He received an NIH Research Merit Award, the Distinguished Andrologist Award of the American Society of Andrology, and the Distinguished Service Award of the Society for the Study of Reproduction.

Board of Advisers

John Amory
M.D., M.P.H.

John is Professor of Medicine and Section Head of General Internal Medicine at the University of Washington where he works as an attending physician on the inpatient medicine wards and in the General Internal Medicine Clinic. John’s research interests are the development of novel forms of male contraception and new approaches to the treatment of men with infertility. He has published more than 114 peer-reviewed papers in the field of male reproduction, and holds current funding from the NIH grant for male contraceptive research, examining the potential utility of inhibitors of testicular retinoic acid biosynthesis as reversible male contraceptives.
Erwin Goldberg
Ph.D.

Erwin is Professor Emeritus at Northwestern University in the department of molecular biosciences. His work focuses on the molecular and cellular biology of mammalian sperm. In particular, his research focuses on a potential male contraceptive targeting lactate dehydrogenase C (LDH-C4), which, when missing in sperm, makes it non-functional. This work has been regularly published in the journal Biology of Reproduction. Erwin is a selected Fellow of the American Association for the Advancement of Science, and has received both the Distinguished Service Award and Distinguished Andrologist Award from the American Society of Andrology, and is a past president of the American Society of Andrology.

David Serfaty
M.D.

David is the founder of the International Consortium on Male Contraception, International Menopause Society, European Society of Gynecology, as well as founder and chair of the French-Speaking Society of Contraception. He serves as president of the College of Medical Gynecology of Paris-Ile-de-France and honorary president of the European Society of contraception and the National Federation of Colleges in Medical Gynecology. He’s a co-author of the book Contraception and over 200 other publications ranging from medical books to peer-reviewed journals. David has also either chaired or been president of the European Society of Contraception, the National Federation of the Colleges in Medical Gynecology, and the Association of the Centers of Birth-Control of AP-HP. And he was the director of the Center of Birth Control and Gynecology; creator and co-director of the University Diploma of Contraception at Lariboisiere-Saint-Louis Faculty, Paris; and director of clinical teaching at Lariboisiere-Saint-Louis Faculty of Medicine.
Nnaemeka Amobi
Ph.D.


Bambang Prajogo
Ph.D.

Bambang is the principal researcher for the male contraceptive Gendarussa developed at Airlangga University in Surabaya, Indonesia. He has led the research through phase I and two phase II clinical trials. His work has been featured on PBS Newshour, The Jakarta Post, The Observer, and The Diplomat.

Michael O’Rand
Ph.D.

Michael is a reproductive biologist and Professor in the Department of Cell Biology and Physiology at the University of North Carolina (UNC) at Chapel Hill, School of Medicine. Michael has more than 40 years of experience in studying mechanisms underlying fertilization. He is currently transitioning from his faculty position at UNC to lead a startup company, Eppin Pharma, to develop a non-hormonal, reversible male contraceptive. Michael is currently researching a non-hormonal male contraceptive with support from the Contraceptive Discovery and Development Branch of the National Institute of Health (NIH). He has 5 issued or pending patents and more than 100 peer-reviewed publications, including in Science.
Gregory S. Kopf
Ph.D.

Greg is the Director of Research and Development for Contraceptive Technology Innovation within Global Health, Population and Nutrition at FHI360 in Durham, NC. In 1982, Greg was the Celso Ramon Garcia Professor of Reproductive Biology in Obstetrics and Gynecology at the University of Pennsylvania School of Medicine. In 2001, he became the Assistant Vice President (and later Interim Vice President) of Discovery, Women’s Health & Bone at Wyeth Pharmaceuticals where he focused on contraceptive development. From 2008-2013 he was the Associate Vice Chancellor for Research Administration at the University of Kansas School of Medicine (KUMC), the Executive Director of the KUMC Research Institute, Inc., and Research Professor of Molecular & Integrative Physiology at KUMC. Greg has served on the editorial boards of several journals; federal advisory committees for the NIH, NSF, and Institute of Medicine; and has served on boards of directors for several non-profit and for-profit organizations/businesses. He currently serves on the National Advisory Child Health and Human Development Council of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Jessie Goodpasture
Ph.D.

Jessie’s work in male contraception began during her PhD studies of Physiology & Biophysics at the University of Illinois Graduate School of Medicine. Her work there included male contraceptive research, some of which focused on development of a reversible vasectomy device. She was recruited to lead Syntex Research’s preclinical development efforts to develop male and female contraceptives, as well as anti-bone resorptive agents for postmenopausal women. Jessie ran a number of Syntex’s clinical development programs including a successful NDA and a Phase II/III program. Jessie was recruited by (now) Quintiles Transnational to perform a turnaround for its West coast operations and subsequently by (now) PRA Health Sciences as a senior manager as well as to establish their West coast operations. Jessie has published 77 peer reviewed journal articles and abstracts, and 10 book chapters. She has served as an NIH Scientific Grant Reviewer, a member of the Mills College Science and Math Advisory Board, and Judge on the International Fellowships Awards Panel for the American Association of University Women.

Statement of Financial Position

<table>
<thead>
<tr>
<th>Acct</th>
<th>Acct_Description</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>1010</td>
<td>WF Checking</td>
<td>$94,428.82</td>
<td>$21,674.63</td>
</tr>
<tr>
<td>1020</td>
<td>WF Savings</td>
<td>$2,850.65</td>
<td>$1,050.09</td>
</tr>
<tr>
<td>1030</td>
<td>PayPal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1499</td>
<td>Undeposited Funds</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>Accounts Payable</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>3000</td>
<td>Unrestricted net assets</td>
<td>$22,724.72</td>
<td>$</td>
</tr>
<tr>
<td>3110</td>
<td>Use restricted net assets</td>
<td>$3,072.00</td>
<td>$</td>
</tr>
<tr>
<td></td>
<td>NET GAIN/LOSS</td>
<td>$71,482.75</td>
<td>$22,724.72</td>
</tr>
</tbody>
</table>

ASSETS $97,279.47 $22,724.72

LIABILITIES and NET ASSET $97,279.47 $22,724.72

Statement of Activities

<table>
<thead>
<tr>
<th>Acct</th>
<th>Acct_Description</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>4010</td>
<td>Individual contributions</td>
<td>$130,736.08</td>
<td>$50,888.34</td>
</tr>
<tr>
<td>4010</td>
<td>Uncategorized Income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5310</td>
<td>Interest-savings/short-term</td>
<td>1.97</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td>TOTAL REVENUE</td>
<td>$130,738.05</td>
<td>$50,888.43</td>
</tr>
</tbody>
</table>

REVENUE

EXPENSES

<table>
<thead>
<tr>
<th>Acct</th>
<th>Acct_Description</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>7020</td>
<td>Grants to other organizations</td>
<td>$8,974.72</td>
<td>$</td>
</tr>
<tr>
<td>7220</td>
<td>Salaries &amp; wages</td>
<td>$33,499.79</td>
<td>$18,523.75</td>
</tr>
<tr>
<td>7250</td>
<td>Payroll taxes</td>
<td>$2,599.98</td>
<td>$1,680.06</td>
</tr>
<tr>
<td>7260</td>
<td>Payroll Service Fees</td>
<td>$50.00</td>
<td>$</td>
</tr>
<tr>
<td>7570</td>
<td>Professional fees - other</td>
<td>$3,083.83</td>
<td>$850.00</td>
</tr>
<tr>
<td>8110</td>
<td>Supplies</td>
<td>$243.90</td>
<td>$393.34</td>
</tr>
<tr>
<td>8130</td>
<td>Telephone &amp; telecommun</td>
<td>$354.80</td>
<td>$678.76</td>
</tr>
<tr>
<td>8190</td>
<td>Internet/Web/Hosting Fees</td>
<td>$104.09</td>
<td>$1,002.15</td>
</tr>
<tr>
<td>8310</td>
<td>Transportation</td>
<td>$364.61</td>
<td>$</td>
</tr>
<tr>
<td>8320</td>
<td>Meals</td>
<td>$1,720.01</td>
<td>$</td>
</tr>
<tr>
<td>8330</td>
<td>Lodging</td>
<td>$1,282.80</td>
<td>$</td>
</tr>
<tr>
<td>8340</td>
<td>Airfare</td>
<td>$5,155.72</td>
<td>$</td>
</tr>
<tr>
<td>8350</td>
<td>Conferences, conventions</td>
<td>$252.58</td>
<td>$3,000.00</td>
</tr>
<tr>
<td>8520</td>
<td>Insurance - non-employee</td>
<td>$790.00</td>
<td>$790.00</td>
</tr>
<tr>
<td>8540</td>
<td>Staff development/Traini</td>
<td>$735.46</td>
<td>$</td>
</tr>
<tr>
<td>8550</td>
<td>Bank fees</td>
<td>$43.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>8590</td>
<td>Other expenses</td>
<td>$</td>
<td>$1,189.65</td>
</tr>
<tr>
<td></td>
<td>TOTAL EXPENSES</td>
<td>$59,255.30</td>
<td>$28,163.71</td>
</tr>
</tbody>
</table>

NET GAIN/(LOSS) $71,482.75 $22,724.72